key: cord-0738326-e8ymzjr5
authors: Wei, Nana; Wang, Qiujing; Lin, Zhibing; Xu, Liyun; Zhang, Zheen; Wang, Yan; Yang, Zhejuan; Li, Lue; Zhao, Tingxiao; Wang, Lu; Lou, Haifei; Han, Mingfang; Ma, Mingliang; Jiang, Yaosheng; Lu, Jinmiao; Zhu, Shilan; Cui, Li; Li, Shibo
title: Systematic profiling of antigen bias in humoral response against SARS-CoV-2
date: 2022-02-14
journal: Virus Res
DOI: 10.1016/j.virusres.2022.198711
sha: 49f76e44d62a3d9269cecd4b3bbba428c968ebab
doc_id: 738326
cord_uid: e8ymzjr5

We know little about the antigen bias in SARS-CoV-2 humoral response and the epitopes of spike recognized by the immune system in asymptomatic (AS) patients and symptomatic (S) patients. Here, we used a microarray to evaluate the humoral immune response in the sera collected from 33 COVID-19-recovered patients up to 1 year. We found that the levels of IgG and IgM induced by the 23 proteins differed significantly in the same patients, and were able to distinguish AS and S patients. The N- and S-specific antibodies were detected even at 12 months after onset. Five epitopes were identified to be associated with the clinical adverse events, and three peptides located in RBD. Overall, this study presents a systemic view of the SARS-CoV-2 specific IgG and IgM responses between AS and S recovered patients and provide insights to promote precise development of SARS-CoV-2 vaccines.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic and rapidly spread around the globe. Up to now, seven coronaviruses can infect humans, and four of them cause the common cold (Cui et al., 2018) . Viruses can induce T-cell and B-cell immune responses. SARS-specific humoral immune response correlates with the T-cell immune response (Grifoni et al., 2020; Ni et al., 2020) . At the beginning of SARS-CoV-2 outbreak, most studies focused on cell entry and the binding receptor (Letko et al., 2020) . Those studies showed that the interaction of spike of SARS-CoV-2 and human angiotensin-converting enzyme 2 (ACE2) plays the key role in SARS-CoV-2 infection (Ejemel et al., 2020; Yi et al., 2020) .

Recent studies have been focusing on the SARS-CoV-2-induced immune response.

Cellular immunity to SARS-CoV-2 is also being evaluated. The number of SARS-CoV-2 specific-CD4+ T cells and CD8+ T cells increase during the first 7-9 days. Pre-existing SARS-CoV-2 cross-reactive T cells have been identified in healthy individuals (Braun et al., 2020; Le Bert et al., 2020) . T follicular helper (T fh ) cells are important in the formation of germinal centers and secretion of cytokines that regulate B-cell response (Kunzli et al., 2020) . The neutralizing antibody titers against spike protein are positively associated with the frequencies of CXCR3+ T fh cells (Crotty, 2011; Zhang et al., 2020) . Both antibodies and SARS-CoV-2-specific T cells are important for the control of primary infection (Dan et al., 2021) .

The spike glycoprotein (S) and the nucleocapsid (N) protein of SARS-CoV-2 are two main viral glycoproteins. The spike is cleaved into an N-terminal S1 and a C-terminal S2 subunit. In the N-terminal, there is a receptor-binding domain (RBD; residues 331-524). Monoclonal antibodies targeting spike have been purified and identified (Chi et al., 2020; Shi et al., 2020; Zost et al., 2020a) . Antibodies targeting spike have been used in clinical therapy, with the purpose of blocking the interaction of ACE2 and spike protein (Bojkova et al., 2020; Zost et al., 2020a; Zost et al., 2020b) .

SARS-CoV-2 infection-and vaccine-elicited spike-specific antibodies are considered important for the control and clearance of SARS-CoV-2 (Poland et al., 2020b; . Several antigens have been used for the evaluation of SARS-CoV-2 humoral immunity (Poland et al., 2020b) .

According to the epidemiological characteristics and trends of SARS-CoV-2, a number of asymptomatic patients have been reported (Nikolai et al., 2020; Zhou et al., 2020) . However, little is known about the persistence and differences of antigen-specific antibodies between asymptomatic patients and symptomatic patients.

A previously developed proteome microarray (Jiang et al., 2020) was modified and was used for the evaluation and screening of SARS-CoV-2-specific IgG and IgM from 33 convalescent patients, with 14 of them followed up to 12 months in this study.

The high mutation rate of SARS-CoV-2 urged us to select conserved peptides in different mutants and develop peptide-based vaccines for the prevention of the disease.

A peptide pool of spike, with 220 peptides included has also been designed into the proteome microarray for the identification of linear B-cell epitopes. To reduce the incidence of side effects and increase the level of neutralizing antibodies, we analyzed the antigen bias in humoral immune response and compared the humoral response between asymptomatic and symptomatic recovered patients.

The cohort study was performed on patients with PCR-confirmed SARS-CoV-2 infection and the basic criteria to define the severity, i.e., mild, moderate, severe and critically severe, are according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (2020) . Asymptomatic infection was determined as a positive result for SARS-CoV-2 RNA by PCR without showing any relevant clinical symptoms. COVID-19 patients were hospitalized and received treatment in Zhoushan Hospital, and were discharged when the standard criteria were met according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). The vital points of the discharge criteria were: (1) normal body temperature; (2) obviously improved respiratory symptoms; (3) obvious absorption of inflammation in the pulmonary imaging; (4) twice consecutively negative for nuclei acid testing. The cohort included 19 asymptomatic and 14 symptomatic individuals with SARS-CoV-2 infection. In total, 30 samples (from 19 asymptomatic and 11 symptomatic) were collected at 1 month after infection, 6 samples (from 6 symptomatic) were collected at 4 months after infection, and 14 samples (from 14 symptomatic) were collected at 12 months after infection. Sera of the control group from healthy donors were collected from Zhoushan Hospital, Zhoushan, China. The serum was collected, processed, and stored by standard protocol (xiling et al., 2020) . All the sera were stored at −80 °C for further analysis.

The Institutional Ethics Review Committee of Zhoushan Hospital, Zhoushan, China approved the protocols used for blood collection from subjects with COVID-19.

Twenty-three proteins of SARS-CoV-2 and 220 peptides of spike were constructed into the proteome array. There were 14 chambers in each slide. Following the instruction previously reported (Jiang et al., 2020) , the PBS buffer containing 0.1% Tween 20 (PBST) and 3% BSA was used to block nonspecific interaction. The pretreated serum was diluted 1:200 in PBST. The diluted serum or buffer was incubated with each well at 4°C overnight. The Cy3-conjugated goat anti-human IgG and Alexa Fluor 647-conjugated donkey anti-human IgM (Jackson ImmunoResearch, PA, USA, Cat#109-165-008 and Cat#709-605-073, respectively) were used to detect the binding antibodies after washing with PBST. The arrays were scanned by LuxScan 10K-A (CapitalBio Corporation, Beijing, China), and the data were analyzed using GenePix Pro 6.0 software (Molecular Devices, CA, USA).

We used the SARS-CoV-2 Surrogate Virus Neutralization Test Kit (Cat. No. L00847) to detect spike-specific neutralizing antibodies . To evaluate the level of peptides induced neutralizing antibodies, the S1-61, S1-66, S1-82, and BSA (100 ng/well) were pre-coated in 96-well plate at 4°C overnight. After washing, 200 µL serum (1:20 diluted with samples dilution buffer) was added, followed by incubation at 37°C for 30 min. After three rounds of absorption, the supernatant was collected for the analysis of inhibitory ability. Briefly, we mixed 60 µL of negative control, positive control, or samples (preincubated or not) with the HRP-RBD solution in a volume ratio of 1:1 and incubated at 37°C for 30 min. Next, 100 µL of each mixture was added to the corresponding wells and incubated at 37°C for 15 min. The plate was washed with washing solution for four times. Then, 100 µL TMB Solution was added to each well and kept in dark at 25°C for 15 min, followed by adding 50 µL stop solution to each well. The absorbance was read at 450 nm immediately using Synergy™ LX Multi-Mode Microplate Reader ((Bio Tek, VT, USA) with Gen5 software (Version 3.05.11). The inhibitory ability was calculated using the formula:

The fluorescence intensities of IgG and IgM were defined as the medians of the foreground for each spot. Then, log2 of the data was taken, and we calculated the value for each protein per group. IgG and IgM data were analyzed separately.

One-way ANOVA, Two-way ANOVA and t test were used for the data analysis.

Q-values or adjusted p-values were obtained using BH (Benjamini and Hochberg) method. The mean signal + three standard deviations (SD) of the negative sera were used to set a cutoff threshold. The values of the samples greater than the threshold were judged as positive (Jiang et al., 2020) . All the Signal intensities were analyzed by the software GraphPad Prism version 8.0. The SARS-CoV-2 proteome microarray data are deposited on Protein Microarray Database under the accession number PMDE258 (http://www.proteinmicroarray.cn/index.php/experiments). Additional data related to this paper may be requested from the authors.

Humoral immunity and cellular immunity can be detected in SARS-CoV-2-infected patients (Ni et al., 2020; Zhang et al., 2020) . Nevertheless, we know little about the differences and persistence of antibodies in asymptomatic and symptomatic SARS-CoV-2 infection. A total of 33 patients and 10 age-matched healthy controls were recruited to this study. To identify SARS-CoV-2-specific linear B-cell epitopes, the microarray was modified by adding 220 peptides ( Figure 1A ). The collected samples were incubated at 56°C for 30 min and stored at −80°C for further analysis (Figure 1 B ).

To explore and analyze IgG and IgM antibodies in asymptomatic and symptomatic patients, 33 COVID-19-recovered patients were assessed using microarray. The detailed information of patients and healthy controls is shown in Table 1 . The recovered patients and healthy controls presented clearly separate clusters for both IgG and IgM data ( Figure 2A and Figure 3A ), and several proteins including N-Cter, N-Nter, RBD, S1 and S distinguished asymptomatic from symptomatic infection ( Figure 2C -2D and Figure 3C -3F). SARS-CoV-2 proteins showed different immunogenicity to elicit humoral IgG and IgM responses ( Figure 2B and Figure 3B ).

The levels of N-Nter-and N-Cter-specific IgG antibodies in symptomatic patients were higher than those in asymptomatic patients ( Figure 2C and 2D). The levels of S-specific IgM antibodies were higher than antibodies elicited by other proteins. Both N-and S-specific IgM antibodies were higher in symptomatic than in asymptomatic patients ( Figure 3C -3F).

According to the data, S and N proteins have the highest sensitivity for the diagnosis, so these two proteins have been applied for the diagnosis of COVID-19 infection (Grzelak et al., 2020; Ni et al., 2020) . The IgM and IgG may be associated with the clinical outcome. Persistent virus stimulation may involve stages of both silent and productive infection without rapidly clearing or even inducing excessive damage to the body (Govindan, 2015) . In clinical studies, SARS-CoV-2 infection has been shown to lead to the impairment of several organs (Robba et al., 2020) . Our present data suggest that the clinical symptoms may be associated with the levels of S-and N-specific antibodies.

The receptor-binding domain (RBD)-specific antibodies have attracted great interest because RBD is the key domain binding human ACE2 (Yi et al., 2020) . Previous studies have mainly focused on the durability of the S-specific antibodies (Zost et al., 2020a; Zost et al., 2020b) . However, nothing is known about dynamics of antibodies induced by other proteins. We utilized the microarray to examine the serum isolated from symptomatic patients at 1 month, 4 months, and 12 months after infection. We analyzed the IgG and IgM profiles for each recovered patient and created heat maps to display the fluorescence intensity ( Figure 4A and 4C). The N-and S-specific IgG and IgM antibodies significantly decreased over time ( Figure 4B and 4D). The NSP9-(50% percentage of all the patients), N protein-(100%) and S-(92.9%) specific IgG antibodies were still detected 12 months after infection ( Figure 4B ). The antibodies against SARS-CoV-2 significantly decreased over time, and most of the antigens-induced IgM antibodies were not detectable 12 months post-infection ( Figure 4D ). Except for RBD-and S-specific IgM, the levels of all the other proteinsspecific IgM decreased to the threshold at 12 months after the onset of infection ( Figure 4D ). Although the serum samples were isolated from COVID-19-recovered patients, the level of RBD-and S-specific antibodies at 4 months post-infection were higher compared with those collected at 1 month. These results indicate that the RBDand S-specific IgG antibodies can persist for at least one year after infection.

The clinical symptoms appeared at the early phase of primary infection, and IgM was the main antibody subtype. In order to explore the correlation between IgM against spike and the clinical symptoms, we used the microarray containing 220 peptides of spike. The top 20 peptides were selected, and the relative intensities of IgM against the peptides were compared ( Figure 5A and 5B). The ratio of the total 20 peptides recognized by IgM antibodies isolated from AS and S patients did not show any significant difference ( Figure 5C ). Four epitopes (S1-4, S1-82, S1-106, and S2-71) exhibited strong discriminatory ability between the AS and S patients using IgM response ( Figure 5D ). These data indicate that the level of IgM is associated with clinical symptoms and the IgM against SARS-CoV-2 with high heterogeneity must be considered in vaccine development.

The Spike-ACE2 interaction plays an important role in SARS-CoV-2 infection.

Identification of antibodies targeting spike has been reported. Yet, we know little about the linear B-cell epitopes of spike recognized by the antibodies. The microarray containing 220 peptides distributed in different areas of spike was used. The top 20 peptides with strong IgG response were identified and analyzed ( Table 2 ). The relative fluorescence intensity is shown in heat map ( Figure 6A ), demonstrating that the 20 peptides have different immunogenicity ( Figure 6B ). Although, 20 peptides were possible to be recognized by most of the sera isolated from both asymptomatic and symptomatic patients, there were only three peptides (S1-61, S1-66, and S1-82) located in the RBD ( Figure 6C ). The ratio of the total 20 peptides recognized by IgG isolated from AS and S patients did not show any significant difference ( Figure 6D ).

Of all different epitopes recognized by IgG isolated from both AS and S patients, S1-61 exhibited strong discriminatory ability between the AS and S patients using IgG response ( Figure 6E ). Amrun, Lee et al designed a peptide pool to explore the association between the response of linear B-cell epitopes and disease severity (Amrun et al., 2020) . Four peptides in spike (S6P2, S14P5, S20P2, S21P2) have been identified in the previous study, and three (S14P5, S20P2, S21P2) of them were confirmed in our study. Moreover, we found that three peptides distributed in RBD were not conserved in different coronaviruses ( Figure 7A ). The crystal structure of spike was downloaded from the Protein Data Bank with accession codes EMD: 30701

and PDB: 7DK3 (closed SARS-CoV-2 S) (Xu et al., 2021) . We utilized Discovery studio 4.1 Client to analyze the location of the three peptides in spike, and found that S1-82 was located on the surface of spike ( Figure 7B and Table 2 ). There are nine amino acid residues reported to be associated with the spike-ACE2 binding affinity (Shang et al., 2020; Yi et al., 2020) . The S1-82 peptide contains two key residues F490 and Q493. The ROC (Receiver Operating Characteristic) curve was constructed, and the peptides S1-82 and S1-61 identified were suitable for detection ( Figure 7C ).

These data indicate that linear B-cell epitopes should be considered in the development of SARS-CoV-2 vaccine.

To evaluate the level of neutralizing antibodies in asymptomatic and symptomatic patients and the peptide-induced neutralizing antibodies, the Virus Neutralization SARS-CoV-2 Surrogate Test Kit purchased from GenScript was used in this study. We found that the level of neutralizing antibodies in symptomatic patients was significantly higher than that in asymptomatic patients ( Figure 8A ). The level of neutralizing antibodies was associated with the antibodies induced by S1 (r=0.68, P=0.0002) and RBD (r=0.68, P=0.0002) ( Figure 8B ). The peptides identified in RBD were able to induce antibodies, but the inhibition abilities of these antibodies have no significance ( Figure 8C ). We also compared the inhibitory ability of serum isolated from symptomatic patients at 1 month, 4 months, and 12 months post-infection. The inhibitory ability of serum isolated at 1 month and 4 months was similar; however, the inhibitory ability of serum isolated at 12 months significantly decreased ( Figure 8D ).

The epitopes identified by antibodies of spike are potential candidates for the development of SARS-CoV-2 vaccine, especially the conserved sequences in spike. We compared the IgG and IgM response between asymptomatic patients and symptomatic patients. The levels of IgG and IgM in symptomatic patients were higher than those in asymptomatic patients. The difference in IgG response is consistent with a previous report (Long et al., 2020) . In contrast, IgM response is not, which may be due to different age ranges ( Circulating IgM antibodies play a key role in controlling infection (Racine and Winslow, 2009) . In this study, we identified five epitopes and five proteins. The level of IgM against these antigens distinguishes asymptomatic from symptomatic patients.

IgM is an important regulator of the complement system (Noris and Remuzzi, 2013; Sharp et al., 2019) . A previous study found that the dysfunction of immune complement was associated with the adverse outcomes (Ramlall et al., 2020) . A hypothesis proposed that the antigen bias in eliciting IgM antibodies against SARS-CoV-2 and the abnormal dynamics of IgM may lead to adverse events.

However, the depletion of IgM memory B cell impaired the immune response and increased mortality in COVID-19 (Lenti et al., 2020) . The selected depletion of IgM or reduction of the level of IgM may relieve the adverse events at the early infection phase. IgM isolated from reverse genetics can be used for the development of modified vaccines, through deleting or replacing the adverse event-associated

epitopes.

An increasing number of SARS-CoV-2 variants are being reported worldwide.

Recently, a variant named B.1.1.7, dominant in UK, presented reduced neutralization by the antibodies of convalescent and vaccinated people (Supasa et al., 2021) . To improve the precision and efficacy of SARS-CoV-2 vaccines, linear B-cell epitopes of spike should be considered in the development of SARS-CoV-2 vaccines. We identified three epitopes in RBD, especially the S1-82 peptide, with great sensitivity and specificity ( Figure 6C ). S1-82 is located on the surface of spike ( Figure 7B ).

Scientists have reported plenty of B-cell epitope-based vaccines (Zhang, 2018) .

Peptide pool or bioinformatics has been utilized in the prediction and identification of SARS-CoV-2 B-cell epitopes (Amrun et al., 2020; Lon et al., 2020) . Several studies have also focused on prediction and identification of T-cell epitopes (Braun et al., 2020; Le Bert et al., 2020) .

The level and affinity of neutralizing antibodies are the two key points to evaluate the vaccines (Krammer, 2020; Poland et al., 2020a) . In the present study, we detected the neutralizing antibodies in AS and S patients and found that the levels of neutralizing antibodies were associated with the intensity of humoral immune response. Because 

Our data indicate that SARS-CoV-2-induced antibodies may provide 12 months of protection. Increasing the humoral response against neutralizing antibody-inducing antigens and decreasing the humoral response against clinical symptom-associated antigens may promote the vaccine efficacy and reduce the incidence of side effects.

Our findings in this study will shed light on the development of the precise and effective vaccine to combat the global COVID-19 crisis. 

The authors declare that they have no conflicts of interest. 

Sequence alignment of S1-61, S1-66, and S1-82 in different coronaviruses. (B) The location of S1-61, S1-66, and S1-82 in spike. Purple marked amino acids represent key residues of predominant binding forces. (C) The sensitivity and specificity of S1-61, S1-66, and S1-82. ability. (C) The inhibitory ability of neutralizing antibodies after absorption of S1-61, S1-66, and S1-82 specific antibodies. For A, p-value was calculated by unpaired t-test, * p <0.05. For C-D, p values were calculated by the One-way ANOVA. Q values were adjusted p-values using BH method. Q-values < 0.05 were considered significant. ns: not significant, * q < 0.05, ** q < 0.01. 

Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7)

Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Follicular helper CD4 T cells (TFH)

Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19

Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible

Overview of complement activation and regulation

Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19

Age-specific mortality and immunity patterns of SARS-CoV-2

SARS-CoV-2 vaccine development: Current Status

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

IgM in microbial infections: taken for granted?

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals

Multi-epitope vaccines: a promising strategy against tumors and viral infections

Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey

Potently neutralizing and protective human antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein